DECAMP-1: Diagnosis and Surveillance of Indeterminate Pulmonary Nodules

Study summary

The goal is to improve the efficiency of the diagnostic follow-up of patients with indeterminate pulmonary nodules by determining whether biomarkers for lung cancer diagnosis that are measured in minimally invasive biospecimens are able to distinguish malignant from benign pulmonary nodules that are incidentally detected in high-risk smokers.

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedBiosample and Imaging Collection

The study team can explain what participation involves.

Who it may be forLung Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Mar 15, 2022 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?15 U.S. locations

Locations may change over time.

Who runs it?Boston University

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: Boston University
Interventions being studied: Other: Biosample and Imaging Collection

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

45 years of age or older;
Initial diagnosis of indeterminate pulmonary nodule (0.7-3.0 cm);
Smoking status: Current or former smoker with ≥ 20 pack years (pack years = number of packs per day X number of years smoked)
Willing to undergo fiberoptic bronchoscopy;
Able to tolerate all biospecimen collection as required by protocol;
Able to comply with standard of care follow up visits including clinical exams, diagnostic work-ups, and imaging for a minimum of two years;
Able to fill out Patient Lung History questionnaire;
Willing and able to provide a written informed consent.

Reasons someone may not be able to joinExclusion criteria

History or previous diagnosis of lung cancer;
Diagnosis of pure ground glass opacities on chest CT;
Contraindications to nasal brushing or fiberoptic bronchoscopy including ulcerative nasal disease, hemodynamic instability, severe obstructive airway disease, unstable cardiac or pulmonary disease; inability to protect airway or altered level of consciousness;
Allergies to any local anesthetic that may be used to obtain biosamples in the study.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Regents of the University of California LA (Los Angeles VA Healthcare System)Los Angeles, California
University of California Los Angeles Medical CenterLos Angeles, California
Naval Medical Center San DiegoSan Diego, California
Denver Research InstituteDenver, Colorado
Walter Reed National Military Medical CenterBethesda, Maryland
Boston University Medical CenterBoston, Massachusetts
Boston VA Research Institute, IncBoston, Massachusetts
Health Research Inc. Roswell Park DivisionBuffalo, New York
Trustees of University of Pennsylvania (Philadelphia VA Medical Center)Philadelphia, Pennsylvania
University of PennsylvaniaPhiladelphia, Pennsylvania
Veterans Research Foundation of PittsburghPittsburgh, Pennsylvania
Middle Tennessee Research Institute (Vanderbilt University)Nashville, Tennessee

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 15, 2022. Always confirm current availability with the study team.

View original record ↗